Amneal Pharmaceuticals (AMRX) Receivables - Other (2017 - 2026)

Amneal Pharmaceuticals' Receivables - Other history runs 10 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• On a quarterly basis, Receivables - Other fell 69.94% year-over-year to $6.2 million in Q1 2026; TTM through Mar 2026 was $6.2 million, a 69.94% decrease from a year earlier, with the FY2025 full-year figure at $5.3 million, up 18.56% from the prior year.
• Receivables - Other grew to $6.2 million in Q1 2026 per AMRX's latest filing, from $5.3 million in the prior quarter.
• Across five years, Receivables - Other topped out at $47.2 million in Q1 2022 and bottomed at $1.7 million in Q2 2022.
• The 5-year median for Receivables - Other is $7.9 million (2024), against an average of $11.8 million.
• Across the five-year window, Receivables - Other jumped 4184.3% in 2022 and sank 93.0% in 2023, its largest moves.
• Year by year, Receivables - Other stood at $9.4 million in 2022, then soared by 61.3% to $15.1 million in 2023, then tumbled by 70.44% to $4.5 million in 2024, then advanced by 18.56% to $5.3 million in 2025, then rose by 16.43% to $6.2 million in 2026.
• Per Business Quant, the three latest AMRX Receivables - Other figures stand at $6.2 million (Q1 2026), $5.3 million (Q4 2025), and $14.8 million (Q3 2025).